1. Home
  2. Stocks
  3. Suvenphar Share Price
  • Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs

    • Suven Pharmaceuticals Share Price

    Large Cap
    ₹1,157.75
    -19.85 (-1.69%)
    • Advice
    • Hold
    18 September, 2024 02:41 BSE: 543064 NSE: SUVENPHAR ISIN: INE03QK01018

    Start SIP in Suven Pharmaceuticals

    Start SIP

    Suven Pharmaceuticals Performance

    Day Range

    • Low 1,147
    • High 1,181
    ₹ 1,157

    52 Week Range

    • Low 518
    • High 1,257
    ₹ 1,157
    • Open Price1,180
    • Previous Close1,178
    • Volume272964

    Suven Pharmaceuticals Chart

    • Over 1 Month + 15.34%
    • Over 3 Month + 60.99%
    • Over 6 Month + 87.16%
    • Over 1 Year + 107.74%

    Suven Pharmaceuticals Key Statistics

    P/E Ratio 122.6
    PEG Ratio -2.8
    Market Cap Cr
    Price to Book Ratio 14.4
    EPS 10.7
    Dividend 0
    Relative Strength Index 62.7
    Money Flow Index 79.4
    MACD Signal 59.02
    Average True Range 49.31

    Suven Pharmaceuticals Investment Rating

    • Master Rating:

    • Suven Pharmaceuticals has an operating revenue of Rs. 934.49 Cr. on a trailing 12-month basis. An annual revenue de-growth of -20% needs improvement, Pre-tax margin of 39% is great, ROE of 14% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 18% and 56% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 32 which is a POOR score indicating inconsistency in earnings, a RS Rating of 86 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 59 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Suven Pharmaceuticals Financials
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 222244213225344364
    Operating Expenses Qtr Cr 139171145127174190
    Operating Profit Qtr Cr 83726897170175
    Depreciation Qtr Cr 121611101111
    Interest Qtr Cr 221112
    Tax Qtr Cr 221817264342
    Net Profit Qtr Cr 65535275124130
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 1,0801,375
    Operating Expenses Annual Cr 615747
    Operating Profit Annual in Cr 410583
    Depreciation Cr 4943
    Interest Annual Cr 75
    Tax Annual Cr 104147
    Net Profit Annual Cr 305433
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 371484
    Cash from Investing Activity Annual Cr -382-236
    Cash from Financing Annual Activity Cr -14-236
    Net Cash Flow Annual Cr -2513
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 2,0561,749
    Fixed Assets Annual Cr 703677
    Total Non Current Assets Annual Cr 1,0311,003
    Total Current Assets Annual Cr 1,210955
    Total Assets Annual Cr 2,2411,958
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 8169
    ROE Annual % 1525
    ROCE Annual % 1932
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 4547
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 231253220231348369
    Operating Expenses Qtr Cr 151180155133181200
    Operating Profit Qtr Cr 80736598167169
    Depreciation Qtr Cr 131713121312
    Interest Qtr Cr 221112
    Tax Qtr Cr 221719264342
    Net Profit Qtr Cr 61534780121124
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 1,1131,387
    Operating Expenses Annual Cr 646774
    Operating Profit Annual in Cr 406567
    Depreciation Cr 5548
    Interest Annual Cr 75
    Tax Annual Cr 105148
    Net Profit Annual Cr 300411
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 358451
    Cash from Investing Activity Annual Cr -362-195
    Cash from Financing Annual Activity Cr -14-236
    Net Cash Flow Annual Cr -1820
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 2,0511,735
    Fixed Assets Annual Cr 788828
    Total Non Current Assets Annual Cr 991955
    Total Current Assets Annual Cr 1,2631,011
    Total Assets Annual Cr 2,2541,966
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 8168
    ROE Annual % 1524
    ROCE Annual % 1931
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 4446
    Invest in Suven Pharmaceuticals

    Suven Pharmaceuticals Technicals

    EMA & SMA

    Current Price
    ₹1,157.75
    -19.85 (-1.69%)
    pointer
    • Bullish Moving Average
    • ___
    • 12
    • Bearish Moving Average
    • ___
    • 4
    • 20 Day
    • ₹1,125.09
    • 50 Day
    • ₹1,016.94
    • 100 Day
    • ₹903.94
    • 200 Day
    • ₹790.69
    • 20 Day
    • ₹1,123.26
    • 50 Day
    • ₹1,002.88
    • 100 Day
    • ₹843.15
    • 200 Day
    • ₹756.29

    Suven Pharmaceuticals Resistance and Support

    PIVOT
    ₹1,162.04
    Resistance
    First Resistance 1,177.02
    Second Resistance 1,196.28
    Third Resistance 1,211.27
    RSI 62.70
    MFI 79.40
    MACD Single Line 59.02
    MACD 56.51
    Support
    First Support 1,142.77
    Second Support 1,127.78
    Third Supoort 1,108.52

    Suven Pharmaceuticals Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 277,993 19,020,281 68.42
    Week 279,663 14,391,479 51.46
    1 Month 414,056 16,185,454 39.09
    6 Month 423,611 18,626,163 43.97

    Suven Pharmaceuticals Result Highlights

    Suven Pharmaceuticals Synopsis

    NSE-Medical-Generic Drugs

    Suven Pharmaceutical is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1024.99 Cr. and Equity Capital is Rs. 25.46 Cr. for the Year ended 31/03/2024. Suven Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 06/11/2018 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24299MH2018PLC422236 and registration number is 422236.
    Market Cap 29,978
    Sales 903
    Shares in Float 12.73
    No of funds 165
    Yield 0.18
    Book Value 14.58
    U/D Vol ratio 3.2
    LTDebt / Equity
    Alpha 0.28
    Beta 0.41

    Suven Pharmaceuticals Shareholding Pattern

    Owner NameJun-24Mar-24Dec-23Sep-23
    Promoters 50.1%50.1%60%60%
    Mutual Funds 14.78%15.26%13.4%12.15%
    Insurance Companies 2.09%1.57%1.89%1.38%
    Foreign Portfolio Investors 9.8%9.54%10.14%10.01%
    Financial Institutions/ Banks
    Individual Investors 10.07%10.51%10.87%11.76%
    Others 13.16%13.02%3.7%4.7%

    Suven Pharmaceuticals Management

    Name Designation
    Mr. Annaswamy Vaidheesh Executive Chairperson
    Dr. V Prasada Raju Managing Director
    Mr. Pankaj Patwari Non Executive Director
    Ms. Shweta Jalan Non Executive Director
    Ms. Matangi Gowrishankar Independent Director
    Mr. Vinod Rao Independent Director
    Mr. K G Ananthakrishnan Independent Director
    Mr. Pravin Rao Udhyavara Bhadya Independent Director

    Suven Pharmaceuticals Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Suven Pharmaceuticals Corporate Action

    Date Purpose Remarks
    2024-08-09 Quarterly Results
    2024-05-30 Audited Results (Revised) per share(100%)Interim Dividend
    2024-02-05 Quarterly Results
    2023-11-09 Quarterly Results
    2023-08-08 Quarterly Results
    Date Purpose Remarks
    2022-09-12 INTERIM Rs.1.00 per share(100%)Interim Dividend
    2022-09-12 SPECIAL Rs.5.00 per share(500%)Special Dividend
    2022-05-17 INTERIM Re.1.00 per shaer (100%) Second Interim Dividend
    2022-05-17 SPECIAL Rs.1.00 per share(100%)Special Dividend
    2022-02-16 INTERIM Rs.1.00 per share(100%)Interim Dividend

    Suven Pharmaceuticals MF Shareholding

    Name Amount(cr)
    UTI Flexi Cap Fund Regular Plan Growth 27,053
    Axis Small Cap Fund Regular Growth 23,772
    Invesco India Contra Fund Growth 17,817
    DSP ELSS Tax Saver Fund Regular Plan Growth 17,488
    HSBC Small Cap Fund Fund Regular Growth 16,905

    Suven Pharmaceuticals FAQs

    What is Share Price of Suven Pharmaceuticals ?

    Suven Pharmaceuticals share price is ₹1,157 As on 18 September, 2024 | 02:27

    What is the Market Cap of Suven Pharmaceuticals ?

    The Market Cap of Suven Pharmaceuticals is ₹29472.3 Cr As on 18 September, 2024 | 02:27

    What is the P/E ratio of Suven Pharmaceuticals ?

    The P/E ratio of Suven Pharmaceuticals is 122.6 As on 18 September, 2024 | 02:27

    What is the PB ratio of Suven Pharmaceuticals ?

    The PB ratio of Suven Pharmaceuticals is 14.4 As on 18 September, 2024 | 02:27

    Q2FY23
    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     
    footer_form

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 29/07/2024 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5Paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.